Jonas Wohlfarth

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

Multidrug Resistant

Patient Reported

Ejection Fraction

Top Venues

Molecular oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Simone Wendlinger, Jonas Wohlfarth, Claudia Siedel, Sophia Kreft, Teresa Kilian, Sarah Junker, Luisa Schmid, Tobias Sinnberg, Ulrich Dischinger, Markus Vincent Heppt, Kilian Wistuba-Hamprecht, Friedegund Meier, Luise Erpenbeck, Elsa Neubert, Matthias Goebeler, Anja Gesierich, David Schrama, Corinna Kosnopfel, Bastian Schilling
Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils. Cancers 16 (9) (2024)
Simone Wendlinger, Jonas Wohlfarth, Claudia Siedel, Sophia Kreft, Teresa Kilian, Sarah Junker, Luisa Schmid, Tobias Sinnberg, Ulrich Dischinger, Markus Vincent Heppt, Kilian Wistuba-Hamprecht, Friedegund Meier, Luise Erpenbeck, Elsa Neubert, Matthias Goebeler, Anja Gesierich, David Schrama, Corinna Kosnopfel, Bastian Schilling
Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils. Cancers 16 (9) (2024)
Jonas Wohlfarth, Corinna Kosnopfel, Dominic Faber, Marion Berthold, Claudia Siedel, Melissa Bernhardt, Andreas Schlosser, Tyler Aprati, David Liu, David Schrama, Roland Houben, Dirk Schadendorf, Matthias Goebeler, Svenja Meierjohann, Bastian Schilling
Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density. Molecular oncology (2024)